Register muted export revenue and stable domestic revenue in India to be expected to increase in the next budgetary year. 5 per cent of overall pharmaceutical exports and 8-10 per cent on domestic pharma is expected.
Speaking about the exports, current PM Narendra Modi has brought up “come make in India” in which is an open invites to life science sectors to make a start. “Due to the recent increase in US regulatory against domestic pharmaceutical companies the growth of exports to the US is likely to be restricted. The export growth to semi-regulated markets also seems likely to get affected by the High depreciation of merging market currencies.”
The expectation growth of overall Indian(Pharma) is 5 per cent in FY17. The outlook has been revised for pharmaceutical sectors for the year 2016-17 from ‘positive’ to ‘stable’, seeking for change for the next budgetary year.
The US Food and Drug Administration (FDA) issued several warning letters and import alerts against Indian facilities on quality related issues.
As of 2015-end, as many as 42 Indian facilities of 28 companies were under import alerts. Pharmaceutical growth continued to decline in FY15 due to the slowdown in export growth, and revenue growth in 12 months ended September 2015 was a little over 7 per cent – the lowest over the last five years.
However, the domestic pharmaceutical market is likely to sustain the recently gained momentum on the back of stable underlying growth drivers and grow at 13-15 per cent in 2016-17, it said.
The statistics and growth is marked so important in the pharma industry for the medical device registration in Indian Healthcare market, the overall growth rate percent and their sectors are
- 8-10 per cent in Sector growth for 2017
- 12.1 per cent in 2015
- 5 per cent in 2015
The increasing healthcare spending by the government, demographic trends, increasing disposable income and higher incidence of lifestyle diseases grows in the domestic market. On Drug price expansion leading to the growth of companies temporarily, increases the volume of sales in the medium term might neutralize the impact.
Other News
India Medical Device Pricing Strategy: Ensuring Growth & Affordability
India’s National Pharmaceutical Pricing Authority (NPPA) is developing a specialized India medical device pricing strategy for medical devices, transitioning away from the conventional drug-centric framework. This innovative strategy will incorporate international pricing tactics tailored to […]
Read MoreImports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read More
ErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read More
TUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read More
